What if cancer could be treated using your own supercharged immune cells?

In this episode of Bullseye Breakdown, host Dustin Weaver sits down with Brian Feth, CEO of Xcellbio, to unpack the future of cancer treatment through immune cell therapy, AI-driven potency testing, and scalable biotech manufacturing.

We cover:

• How CAR-T therapies are shifting from “last resort” to front-line treatment

• Why scaling biotech is like surgery — not software

• How AI and impedance readers are changing the way we measure cancer-fighting potency

• Building a platform that helps cure patients and generate revenue before FDA approval

• The emotional toll of biotech — and how to lead through it

Brian also shares the worst advice he ever received, and how his team has built a company that’s saving lives — and scaling with grit.

If you care about cancer research, biotech startups, or what it takes to grow a mission-driven business in a brutal industry, this one’s a must-listen.

🎯 Follow Bullseye Breakdown for unfiltered founder stories that aim higher.